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This study investigates the influence of genetic variation of the estrogen receptor alpha (ESR1) gene locus on
several bone parameters in 2042 individuals of The Rotterdam Study, a prospective population-based cohort
study of elderly subjects. We analysed three polymorphic sites in the 50 region of the ESR1 gene; a (TA)n-
repeat in the promoter region, and molecular haplotypes of the PvuII and XbaI RFLPs in intron 1, and inferred
long-range haplotypes (LRH) thereof. We observed only three of the possible four PvuII–XbaI haplotypes in
our population. A comparison with other Caucasian populations showed similar haplotype frequencies, while
in Asian and African populations these were different. Linkage disequilibrium (LD) analysis between the
PvuII–XbaI haplotype and the (TA)n repeat showed strong LD between the two sites. Reconstruction of long
range haplotypes over the entire 50 region, revealed six frequent LRH. In men, we did not observe an
association between the ESR1 polymorphisms studied and bone parameters. In women, we demonstrated an
allele dose effect of haplotype ‘px’ (P¼ 0.003) and a low number of (TA)n repeats (P¼ 0.008) with decreased
lumbar spine bone mineral density (BMD) (4.8% lower BMD in women homozygous for haplotype ‘px’,
representing 28% of the population, compared with homozygous non-carriers) and decreased vertebral bone
area (2.3% difference between extreme genotypes; P¼ 0.016). Most importantly, we found an increased
vertebral fracture risk with evidence for an allele dose effect with an odds ratio of 2.2 (95%CI 1.3–3.5) for
haplotype ‘px’, and 2.0 (1.5–3.2) for a low number of (TA)n repeats. The ESR1 genotype dependent fracture
risk is largely independent of BMD and bone area. Combination of risk alleles at both loci by long-range
haplotyping improved the associations slightly, but because of the strong LD between the two polymorphic
sites, we were unable to determine if any particular polymorphic site is driving the associations found. We
conclude that ESR1 polymorphism in the 50 (promoter) region is associated with vertebral fracture risk,
lumbar spine BMD and vertebral bone area in postmenopausal women, but not in men. The molecular
mechanism underlying this association needs further study.
INTRODUCTION
Osteoporosis is characterized by low bone mineral density (BMD)
and an increased risk of fractures (1). Osteoporosis is considered
to be a multifactorial syndrome with environmental and genetic
factors interacting. Twin studies have suggested that up to 75% of
the variance in BMD is genetically determined (2,3). Genetic
variations in several genes are thought to be responsible for this
genetic component and one of the potential candidates is the
estrogen receptor alpha (ESR1) gene.
Several lines of evidence show the important role of the
estrogen endocrine system in the regulation of BMD and the
occurrence of osteoporosis. Exposure to low estrogen levels
occurring after menopause in women is associated with
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increased risk for osteoporosis. The serum level of estradiol has
been shown to be an important predictor of subsequent bone
mass (4) and risk for osteoporotic fractures (5,6). In line with
this, estrogen replacement treatment in early postmenopausal
women decreases the risk of osteoporotic fractures (7–9).
Estrogens exerts its effect primarily via the ESR1 and the
pivotal role of ESR1 in the regulation of bone mass was
suggested by a report of a young adult male with a loss-of-
function mutation of the ESR1 gene resulting in a phenotype
with low BMD (10). Consistent with this, an ESR1 knockout
mouse model showed that both female and male mice had
decreased bone mass (11).
Several genetic variations in the ESR1 gene have been
described and associations of these polymorphisms with BMD
have been reported, but results have been inconsistent (12–21).
In part, this is due to the limited sample size of most studies
where lack of power can lead to spurious results. In addition,
differences between populations can play a role, such as
ethnicity, age, environment and genetic make-up. Most studies
focused on women and have not analyzed fractures, the
clinically most relevant endpoint of osteoporosis.
We analyzed three polymorphic sites in the 50 end of the
ESR1 gene. These were a (TA)n VNTR located approximately
1 kb upstream of the first exon, and the PvuII and XbaI
restriction fragment length polymorphisms (RFLPs) (22) in
intron 1, about 400 bp upstream of exon 2. Since no functional
effect of these sequence variations on expression or function of
the ESR1 protein has been established so far, they were treated
essentially as anonymous polymorphisms. In association
studies they are therefore considered as markers and associa-
tion can be explained by linkage of marker alleles with a truly
functional allele elsewhere in the gene. We hypothesize that
genetic variation in the ESR1 gene could lead to differences in
mRNA expression, which might result in different responsive-
ness to circulating levels of its ligand estrogen, which in turn
results in genotype-dependent differences in bone mass, bone
metabolism and fracture risk.
Therefore, we investigated, in a large and homogeneous
population-based sample of Caucasian elderly men and
women, the influence of the ESR1 polymorphism on BMD,
vertebral bone area and fractures and compared our results with
those obtained in other association studies.
RESULTS
Baseline characteristics
Table 1 shows the baseline characteristics of the total study
population and also for the subgroup for whom vertebral
fracture data were available. The individuals in the vertebral
fracture study were on average 2 years younger, but none of the
other baseline characteristics were significantly different.
Genotype and allele frequencies
Table 2 shows the genotype distribution according to PvuII–
XbaI RFLP haplotypes in men and women. Genotypes were
found to be in Hardy–Weinberg equilibrium (HWE; P¼ 0.96
and 0.99, respectively, for men and women). Table 3 shows the
frequencies of the haplotypes found in our cohort of women,
compared with those in other populations of women. The
frequencies of the haplotypes were similar in other Caucasian
populations, but in two Asian populations haplotype 3 (Px) was
more frequent, while the haplotype 2 (PX) allele was less
frequent. In the small African population tested (Coriell panel),
haplotype 1 was less frequent than in Caucasian and Asian
women, and haplotype 2 was more frequently present. In all
populations the haplotype 4 ( pX) was rare or not present at all.
The frequencies of the (TA)n VNTR alleles in our total
population are shown in Figure 1. The bimodal distribution of
VNTR alleles is similar to that found in earlier studies of
Caucasians. The (TA)n genotype data were not available for
other ethnic groups or could not be determined because of low
power due to small sample size and the large number of alleles.
LD and haplotype analysis PvuII–XbaI and
the (TA)n VNTR
LD-analysis showed strong LD between the (TA)n-repeat and
PvuII–XbaI haplotype. In order to get more insight into the
pattern of linkage disequilibrium between the two polymorphic
loci, pairwise disequilibria measures (D0) between the three
different PvuII–XbaI haplotypes and all the different (TA)n-
repeat alleles were calculated. Figure 2 shows that haplotype 1
is in strong (although not complete) LD with a low number of
(TA)n-repeat, while haplotype 2 is linked to a longer (TA)n
repeat and haplotype 3 is not in LD with the (TA)n VNTR.
We went on to reconstruct long range haplotypes (LRH) of
PvuII–XbaI RFLP haplotypes and the (TA)n-VNTR alleles. The
(TA)n VNTR is located at a distance of 35 kb from the two RFLPs
so molecular haplotypes of all three polymorphisms cannot
easily be determined. Instead, haplotypes frequencies were
inferred based on genotype frequencies of individual poly-
morphisms using a Markov chain–Monte Carlo algorithm (23)
Table 1. Baseline characteristics of the total study population and the subgroup
for whom vertebral fracture data are available
Study
population
Study
population
vertebral
fractures
P-value
Women
Number 1100 657
Age (years) 67.0 6.9 65.7 6.4 <0.001
BMI (kg/m2) 26.2 3.7 26.0 3.7 0.55
FN-BMD 0.80 0.12 0.81 0.12 0.13
LS-BMD 1.01 0.17 1.02 0.17 0.73
Age of menopause
(years)
48.7 4.9 48.7 5.0 0.97
Age at menarche
(years)
13.7 1.7 13.7 1.8 0.67
Men
Number 942 527
Age (years) 67.3 7.1 65.4 6.5 <0.001
BMI (kg/m2) 25.5 2.9 25.6 2.8 0.50
FN-BMD 0.87 0.13 0.88 0.13 0.20
LS-BMD 1.15 0.20 1.15 0.19 0.81
Values are means standard deviation.
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for haplotype reconstruction of each individual (Table 4).
Owing to the strong LD, we observed two frequent LRHs (L-1
and H-2) among the six possible haplotypes. While 88% of the L
(TA)n VNTR alleles are linked to the PvuII–XbaI haplotype 1,
only 69% of H (TA)n alleles are in LD with the PvuII–XbaI
haplotype 2. This reflects the differences in D0 as shown in
Figure 2. We then analyzed association of ESR1 polymorphism
with bone characteristics for the PvuII–XbaI haplotypes and the
(TA)n VNTR separately and for the combined LRHs.
PvuII–XbaI haplotype and bone characteristics
We investigated the relation between each of the three PvuII–
XbaI haplotypes and BMD, using linear regression analysis.
For each haplotype, subjects were grouped according to the
number of copies of the haplotype under investigation.
Haplotype 1( px) showed a significant association with
decreased BMD at the lumbar spine (LS-BMD) in women
(Table 5), while haplotype 2 was associated with increased LS-
BMD and haplotype 3 did not show an association. Baseline
characteristics according to the haplotype 1 carrier status
showed that, in both genders, age and body mass index
(BMI) did not differ significantly between the genotypes
(results not shown), while, as was previously found in women,
age at menopause differed significantly (24). The mean age at
menopause was 0.6 years higher for every copy of haplotype 1
(P¼ 0.005, linear regression). No significant difference was
found for age at menarche. Table 5 shows also vertebral bone
area measures according to haplotype 1 genotype, which was
significantly different between the different genotypes in
women. In men, no association was found between the
haplotype 1 genotype and BMD or bone area measures. In
all analyses, additional adjustment for baseline age, BMI and
age at menopause did not essentially change the associations.
Table 6 shows the number of fractures and odds ratios
according to haplotype 1 carrier status. We found no association
of the haplotype 1 with risk for non-vertebral fracture, neither in
men nor in women. We did additional analyses for different
types of non-vertebral fracture, like hip, upper humerus and
wrist, but we could not find a significant association of the
haplotype 1 for any of these different types of fractures. For
women we found a significantly increased risk for vertebral
fractures in haplotype 1 carriers. We found evidence for an
allele dose effect in which the risk increased 2.0 (1.4–2.9) times
per copy of the haplotype 1. In view of the possible confounding
effect of vertebral fractures on vertebral bone area, we adjusted
the associations of vertebral bone area for presence or absence
of vertebral fractures and found no effect of this adjustment on
the association. In an additional analysis, we have excluded the
fracture cases and found that the association between bone area
and ESR1 polymorphism was still present (data not shown).
This strongly suggests that the effect of ESR1 variation on bone
area is independent of fractures.
In view of these results and the strong LD between the PvuII–
XbaI haplotype and the (TA)n VNTR, we went on to analyze
the (TA)n VNTR associations to bone characteristics, in women
only and only for lumbar spine BMD, vertebral bone area and
only for vertebral fracture risk.
The (TA)n VNTR and bone characteristics
We investigated the relation between each (TA)n VNTR allele
and bone characteristics by grouping the women according to
Figure 1. Allele frequencies of (TA)n VNTR polymorphism in the total study
population. L¼ low number of TA repeats; H¼ high number of TA repeats.
Figure 2. Pairwise disequilibrium coefficients (D0) between the three PvuII–
XbaI haplotype alleles and the 13 most common (TA)n repeat alleles. The coef-
ficient is positive when the alleles are linked, and is negative when the alleles
exclude each other. When D0 is 1, the two alleles are completely linked, when
D0 is 1, the two alleles exclude each other completely.
Table 2. Genotype distribution according to PvuII–XbaI haplotypes
Genotype Men number (frequency) Women number (frequency)
11 275 (29.2) 311 (28.3)
12 350 (37.2) 421 (38.3)
13 122 (13.0) 127 (11.5)
22 105 (11.1) 142 (12.9)
23 76 (8.1) 86 (7.8)
33 14 (1.5) 13 (1.2)
Total 942 (100) 1100 (100)
1¼ px; 2¼ PX; 3¼ Px.
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carrier status of the individual (TA)n VNTR allele under
investigation. Table 7 shows that all carriers of alleles with a
low number of (TA)n repeats (n< 18) have a higher percentage
of vertebral fractures rather than one or two individual (TA)n
alleles. The same was observed for the association with lumbar
spine BMD. However, for the vertebral bone area we did not
observe such a clear pattern of association.
Based on the results described above, and the clear bimodular
distribution of the (TA)n VNTR alleles, the (TA)n alleles were
grouped into a high number of repeats (n 18, allele H) and a
low number of repeats (n< 18, allele L) and association
analysis between genotype and bone characteristics was
repeated. Similar results were found with the L-allele of the
TA-VNTR when compared with the haplotype 1 associations.
The short (TA)n VNTR was associated with decreased BMD at
the lumbar spine and decreased lumbar spine bone area in
women.
Differences were 4.8 and 2.2%, respectively, between
the extreme genotype groups LL and HH. Similar to the
haplotype 1, we found a significant association with vertebral
fractures in women, and we did not find an association with
non-vertebral fractures (results not shown). Again we found
evidence for an allele dose effect with vertebral fracture risk
increasing 2.2 (95% CI 1.5–3.1) per copy of the L-allele of the
(TA)n VNTR, and this risk was independent of the possible
confounding factors age, BMI, lumbar spine BMD, lumbar
spine bone area and age at menopause (data not shown).
Long-range haplotypes of PvuII–XbaI haplotypes and
the (TA)n-VNTR and bone characteristics
In order to determine which of the polymorphic sites at the 50
region of the ER gene is driving the associations with bone
end-points, we repeated the association analysis with the six
observed LRHs. Table 8 shows the difference between carriers
and non-carriers of the particular LRH with respect to
percentage of vertebral fractures, mean lumbar spine BMD
and mean vertebral bone area.
For vertebral fractures, all LRHs with a low number of TA
repeats show a higher percentage of vertebral fractures in
carriers compared to non-carriers. This pattern was not seen for
BMD and bone area measures. However, the largest effect was
always observed for the LRH allele A, which is the
combination of a low number of TA repeats and PvuII–XbaI
haplotype 1. This is also reflected in Table 9, where the
three different risk alleles (PvuII–XbaI haplotype 1, TA-L and
LHR-A) are compared for their strength of association. The
long-range haplotype A (the combination of the haplotype px
and VNTR allele L) shows a small improvement of the
associations compared with the individual risk alleles.
DISCUSSION
This study shows an association between the PvuII–XbaI
haplotype and the (TA)n repeat in the ESR1 gene with lumbar
spine BMD, vertebral bone area and vertebral fracture risk in
postmenopausal women. No association was found with
femoral neck BMD and non-vertebral fractures. In men, no
significant association with bone characteristics was found. We
demonstrated that in our population the PvuII–XbaI haplotype
and the (TA)n VNTR are in strong LD, which makes it very
difficult to determine which one of the two polymorphic sites is
driving the associations with these bone characteristics.
Several studies in women have reported inconsistent
associations between polymorphism of the ESR1 gene and
BMD (12–21). The existence of ethnic differences between the
populations, the case–control designs and a health-based
selection bias in several studies could explain the discordant
findings. The present study confirms data of a number of
previous studies (12,14,20,25). In contrast, two other studies
found the PvuII–XbaI haplotype 3 (Px) to be associated with
decreased BMD (13,15), whereas others showed no association
(16,18,26). Statistical reasons (such as lack of power and study
design) could contribute to the contradictory results published
so far. In addition, our findings together with those of others
suggest that there could be allelic heterogeneity at the ESR1
locus among different populations. This should be accom-
panied with differences in genotype distributions, which we
indeed found when we studied the allelic frequencies among
Table 3. PvuII–XbaI haplotype frequencies in women with several ethnic backgrounds
Ethnic origin Number of subjects Country (reference) Haplotype
1 ( px) 2 (PX) 3 (Px) 4 ( pX)
Caucasian 1100 The Netherlands (this study) 53.0 36.1 10.9 0
Caucasian 610 Italy (14) 52.1 40.9 5.7 1.3
Caucasian 454 Denmark (16) 53.0 33.7 13.3 0
Caucasian 206 United Kingdom (13) 56.1 33.5 9.2 1.2
Asian 238 Japan (15) 54.5 18.7 26.5 0.3
Asian 598 Korea (18) 57.7 18.5 21.5 2.3
African 19 Coriell panel 36.8 50.0 13.6 0
Table 4. Estimated frequencies of long range haplotypes from PvuII–XbaI
haplotype alleles and (TA)n alleles
a in 1100 women
LRH haplotype (TA)n PvuII–XbaI Number of alleles (%)
A L 1 1065 (48.4)
B L 2 59 (2.7)
C L 3 54 (2.5)
D H 1 105 (4.8)
E H 2 732 (33.3)
F H 3 185 (8.4)
Total 2200 (100)
aThe (TA)n alleles are defined as L (n< 18) and H (n 18).
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different ethnic populations. The two Asian populations studied
(15,18) showed different frequencies of the haplotypes 3 (Px)
and 2 (PX) compared with the Caucasian populations, while in
the small African study sample the haplotype 1 ( px) was
present at lower frequency. A different degree of LD between
the polymorphism studied and the true functional polymor-
phism in the different populations might be another reason for
the inconsistent results concerning association studies between
ESR1 variations and bone characteristics. Our findings of the
association with vertebral fractures are in line with those of
Langdahl et al. (12) and Becherini et al. (14). These case–
control studies reported results using the TA-VNTR in the
promoter region and found a lower mean number of TA repeats
present in individuals with osteoporotic fractures. Interestingly,
the increase in fracture risk we found in the present population-
based study was not explained by the relatively modest 0.2 SD
difference in BMD between the genotypes. We observed the
ESR1 genotype association with vertebral fractures to be
independent of lumbar spine BMD and of age at menopause.
Whereas the assessment of BMD is to some extent ESR1-
dependent, and as such indirectly influences the risk of
fractures, the BMD-independent relation of ESR1 genotype
with fractures suggests that other underlying biological
mechanisms than those reflected in BMD explain the increased
Table 5. Bone measures (mean SD) according to ERa genotype for PvuII–XbaI haplotype 1
Bone measures Number of copies of PvuII–XbaI haplotype 1 P-value
0 1 2
Women n¼ 240 n¼ 548 n¼ 311
Femoral neck BMD (g/cm2)
Crude 0.81 0.12 0.81 0.12 0.80 0.13 0.36
Adjusteda 0.81 0.11 0.81 0.12 0.80 0.10 0.22
Lumbar spine BMD (g/cm2)
Crude 1.03 0.17 1.02 0.17 0.99 0.16 0.006
Adjusteda 1.04 0.15 1.02 0.16 0.99 0.15 0.001
Lumbar spine bone area (cm2)
Crude 43.3 4.3 42.5 4.6 42.3 4.4 0.01
Adjusteda 43.3 4.5 42.6 4.5 42.3 4.5 0.02
Men n¼ 195 n¼ 472 n¼ 274
Femoral neck (g/cm2)
Crude 0.87 0.14 0.87 0.13 0.86 0.13 0.26
Adjustedb 0.88 0.13 0.87 0.13 0.86 0.13 0.08
Lumbar spine (g/cm2)
Crude 1.15 0.19 1.16 0.20 1.15 0.20 0.68
Adjustedb 1.16 0.19 1.16 0.18 1.15 0.18 0.41
Lumbar spine bone area (cm2)
Crude 51.8 5.2 51.5 5.3 52.2 5.6 0.28
Adjustedb 51.9 5.3 51.5 5.2 52.2 5.3 0.45
aValues are adjusted for age, BMI and age at menopause.
bValues are adjusted for age and BMI.
P-values were calculated using linear regression analysis.
Table 6. Fracture risk according to PvuII–XbaI haplotype 1 carrier status
Womena number of copies of Menb number of copies of
PvuII–XbaI haplotype 1 PvuII–XbaI haplotype 1
0 1 2 0 1 2
Non-vertebral
No. fractures/total no. (%) 31/241 (12.9) 84/548 (15.3) 35/311 (11.3) 13/195 (6.7) 29/472 (6.1) 16/275 (5.8)
OR crude 1 1.2 (0.8–1.8) 0.9 (0.5–1.4) 1 0.9 (0.5–1.8) 0.9 (0.4–1.8)
OR adjusted 1 1.2 (0.8–1.9) 0.8 (0.5–1.4) 1 0.9 (0.5–1.8) 0.8 (0.4–1.7)
Vertebral
No. fractures/total no. (%) 9/146 (6.2) 37/318 (11.6) 41/193 (21.2) 13/104 (12.4) 23/254 (9.1) 29/169 (17.2)
OR crude 1 2.0 (0.9–4.3) 4.1 (1.9–8.8) 1 0.7 (0.3–1.4) 1.5 (0.7–2.9)
OR adjusted 1 2.0 (0.9–4.3) 4.0 (1.9–8.7) 1 0.6 (0.3–1.4) 1.3 (0.6–2.8)
OR¼ odds ratios; OR are presented with 95% confidence intervals.
aValues are adjusted for age, BMI, age at menopause and BMD (non-vertebral type of fractures were adjusted for femoral neck BMD, vertebral fractures for lumbar
spine BMD and lumbar spine bone area).
bValues are adjusted for age, BMI and BMD (non-vertebral type of fractures were adjusted for femoral neck BMD, vertebral fractures for lumbar spine BMD and
lumbar spine bone area).
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fracture risk. This same phenomenon was also observed for the
relation between the collagen-type Ialpha1 Sp1 polymorphism,
BMD and fracture risk (27), and for VDR polymorphisms (28).
This suggests that BMD might not be the most suitable
endpoint in genetic association studies for osteoporosis, at least
for these candidate genes. In addition, it indicates that these
genetic markers might be used to predict fracture risk
independently or in combination with BMD measurements.
We also found an association of ESR1 polymorphism with a
parameter of bone geometry, total vertebral bone area. This
association was independent of the association with vertebral
fractures and suggests a relation between ESR1 polymorphism
and bone size. Therefore, we hypothesize that ESR1 poly-
morphisms leads to a difference in bone growth, which might be
explained by a genotype-dependent estrogen sensitivity locally
at the site of bone growth. In support of this hypothesis, we
recently found an association of ESR1 polymorphism with
stature (29). Together with our previous observation of
the genetic effect of ESR1 polymorphism on menopausal
status (24), and associations with cardiovascular disease (30) and
cancer (31), this illustrates the pleiotropic nature of the ESR1
protein. The estrogen endocrine system can be simultaneously
involved in several different metabolic pathways, such as the
reproductive system, bone and cardiovascular function.
Our study has some potential limitations. Vertebral fracture
data were only collected in individuals that survived the follow-
up period of approximately 7 years. Although this results in a
healthy responder bias this is not likely to be genotype-
dependent, since we did not find an influence of the ESR1
polymorphisms we studied on survival (data not shown) and,
therefore, we do not expect this to influence our results.
Genetic association studies can be influenced by population
heterogeneity. In this cohort study, all subjects were Dutch
Caucasians; to our knowledge no systematic differences were
present with respect to the part of The Netherlands in which
this study was performed. Therefore our study population
might be considered as an ethnically homogeneous and
representative sample of the Dutch subjects.
The results from this study clearly show strong linkage
disequilibrium between the (TA)n VNTR in the promoter and the
PvuII–XbaI haplotypes in the first intron of the gene. Previous
studies also showed a strong relationship between the two
polymorphic sites, however we determined the pattern of linkage
disequilibrium between the two polymorphic sites in detail
and tried to assess which one of the polymorphisms is driving
the associations. Although some earlier studies suggested one of
the polymorphisms to have stronger effects than the others, we
were unable to distinguish the different effects of the two
polymorphic sites because of the strong linkage between them
despite the large population we had available to study. However,
the association studies with the long range haplotypes tend to
suggest that both sites are contributing, since a particular long
range haplotype shows the strongest effects on the different bone
parameters and fracture risk.
The PvuII and XbaI polymorphic sites are located in an
intron, and so far it is not known whether they have functional
consequences. However, polymorphisms in introns could affect
mRNA production, since introns have been recognized to
contain regulatory sequences. A well-known example is the
Sp1 polymorphism located in the first intron of the collagen-
type Ialpha1 gene, which is known to change the mRNA
production of the gene which eventually leads to decreased
BMD an increased fracture risk (27,32). The PvuII–XbaI
polymorphic site in the first intron of the ESR1 gene could
influence gene expression in a similar manner. Recently, a
report showed that the PvuII polymorphism is located within a
potential bMyb binding site, which was able to regulate
transcription efficacy of a reporter gene (33). Alternatively,
the location of a variable length of the (TA)n VNTR in the
promoter of the ESR1 gene could also affect gene transcription.
Previous studies have shown that a VNTR in proximity to a
promoter can have a significant influence on transcriptional
regulation (34–36). However, it is still possible that yet another
third polymorphic site linked to the ones studied here is the true
functional sequence variation. The only way to clarify this issue
is to identify all polymorphisms in this region of the gene and
perform functional studies on these polymorphisms.
A loss of function mutation in ESR1 leading to low BMD
was initially reported in a young adult male. However, in the
present study we showed that the associations observed were
present in women but not in men. For fractures, this might
simply be explained by lack of statistical power due to the
lower number of fractures observed in men. In that respect one
should keep in mind that, although the present population study
includes a large number of individuals, exact estimation of the
fracture risks and the size-effect of the BMD-association can
only be determined by meta-analysis of all data. The difference
between men and women with respect to the associations found
can be explained by the higher circulating estrogen levels in
elderly men compared with postmenopausal women, which
may mask the differences between genotypes.
The associations were strongest at the spine (i.e. with lumbar
spine BMD and with vertebral fractures). This is in line with
previous data showing a higher response to estrogen replacement
therapy at the lumbar spine in contrast to the femoral neck
(19,37–39). Probably, the effect of the ESR1 is more pronounced
Table 7. Differences in mean BMD of the lumbar spine and percentage of
vertebral fractures between women carrying the test (TA)n allele and women not
carrying the test allele
Number
of (TA)n
Number of
carriers
D percentage
vertebral
fracturesa
DLS
BMDb
DLS bone
areac
13 153 þ9.6 0.022 0.50
14 543 þ4.7 0.015 þ0.29
15 194 þ2.8 0.002 0.93
16 54 þ6.2 0.014 0.76
17 63 þ7.8 þ0.008 þ0.32
18 25 5.0 þ0.018 1.09
19 78 5.4 þ0.012 0.27
20 59 8.1 0.036 þ0.82
21 187 7.1 þ0.02 þ0.75
22 170 2.2 þ0.011 0.10
23 237 3.6 þ0.009 þ0.39
24 144 5.1 þ0.025 þ0.62
25 37 3.9 0.033 0.66
aPercentage of vertebral fractures in allele-carriers minus that of non-carriers.
bMean BMD of allele-carriers minus mean BMD of non-carriers.
cMean vertebral bone area of allele-carriers minus that of non-carriers.
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in the vertebral body, which is rich in trabecular bone, due to a
higher bone turnover rate. Trabecular bone has a higher rate of
bone turnover than cortical bone because trabecular bone
presents relatively more surface per unit of bone volume.
We conclude that the PvuII–XbaI RFLP-haplotype and the
(TA)n-VNTR in the ER gene are associated with lumbar spine
BMD, vertebral bone area, and vertebral fracture risk in
postmenopausal women. This risk is independent of BMD
differences or other confounding factors. Combination of
risk alleles at both loci by long-range haplotyping improved
the associations slightly, but because of the strong linkage
disequilibrium between the two polymorphic sites, we
were unable to determine if any particular site is driving
the associations. Further studies are needed to elucidate the
exact molecular mechanism underlying this association.
MATERIAL AND METHODS
Study population
Subjects were participants of the Rotterdam Study, a prospective
population based cohort study of individuals aged 55 years and
over. The study was designed to investigate the incidence of, and
determinants of, chronic disabling diseases. Rationale and design
have been described previously (40). The Rotterdam Study was
approved by the Medical Ethics Committee of Erasmus University
Medical School and written informed consent was obtained from
each subject. All 10 275 inhabitants aged 55 years and over of a
district in Rotterdam, The Netherlands, were invited for baseline
examination between August 1990 and June 1993. Of those, 7983
participated. Baseline measurements of bone mineral density were
available for 5931 independently living subjects from the study, but
1453 of these were excluded on the basis of age (>80 years), use of
a walking aid, known diabetes mellitus or use of diuretic, estrogen,
thyroid hormone or cytostatistic drug therapy. From the 4478
remaining subjects, we studied a random sample of 2042 subjects.
In addition, we determined allele frequencies in a panel of
subjects of African origin from the Coriell Institute (Camden, NJ,
USA), which consists of 10 African-American subjects (HD04)
and nine African subjects from south of the Sahara (HD12).
Clinical examination
At baseline, BMD (expressed in g/cm2) was measured at the
femoral neck and BMD and average vertebral bone area (cm2)
was measured over the L2–L4 of the lumbar spine by dual
energy X-ray absorptiometry (DEXA, Lunar DPX-L densito-
meter, Lunar Corp., Madison, WI, USA) as described
previously (41). Height and weight were measured in
standing position in indoor clothing without shoes. BMI was
computed as weight in kilograms divided by height in
meters squared (kg/m2). Menopause status and age at menarche
was assessed and validated as described previously (24).
Vertebral fracture assessment
Both at baseline and at a follow-up visit, between 1997 and
1999, thoracolumbar radiographs of the spine were obtained.
The follow-up radiographs were available for 1184 individuals,
Table 8. Association of the six PvuII–XbaI (TA)n repeat LRH alleles in 1100 women with BMD and bone area of the spine
LRH allele Haplotype alleles
(TA)n, PvuII–XbaI
Number of carriers D percentage vertebral
fracturesa
DLS BMD (g/cm2)b DLS bone area (cm2)c
A L, 1 797 þ9.3 0.028 0.78
B L, 2 57 þ5.1 þ0.026 þ0.20
C L, 3 51 þ3.0 0.005 þ0.16
D H, 1 100 3.4 þ0.009 þ0.41
E H, 2 604 8.2 þ0.019 þ0.55
F H, 3 174 3.8 þ0.010 þ0.06
L¼ low number of (TA)n repeats (n< 18); H¼ high number of (TA)n repeats (n 18).
aPercentage of vertebral fractures in allele-carriers minus that of non-carriers.
bMean BMD of allele-carriers minus mean BMD of non-carriers.
cMean vertebral bone area of allele-carriers minus that of non-carriers.
Table 9. Associations in 1100 women with vertebral fracture risk, lumbar spine BMD and vertebral bone area by ESR1 genotype as defined by the PvuII–XbaI
haplotype, the (TA)n VNTR, and the combination thereof (the LRH)
Odds ratiosa per copy
of the allele
P-valueb DLS-BMDc (g/cm2)
per copy of the allele
P-valueb DLS bone aread (cm2) per
copy of the allele
P-valueb
PvuII–XbaI haplotype 1 2.0 [1.4–2.9] <0.001 0.0208 0.003 0.465 0.016
(TA)n VNTR L 2.2 [1.5–3.1] <0.001 0.0183 0.008 0.474 0.013
LRH allele A 2.2 [1.5–3.1] <0.001 0.0220 0.002 0.540 0.005
aOdds ratios are presented with 95% confidence intervals; odds ratios are adjusted for age, BMI and lumbar spine BMD.
bP-values are calculated using linear regression.
cBMD values are adjusted for age and BMI.
dVertebral bone area values are adjusted for age and BMI.
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who survived after an average 7.4 years after baseline center
visit and who were still able to come to our research center. All
follow-up radiographs were scored for the presence of vertebral
fracture by the McCloskey/Kanis method (42) as described
earlier (43). If a vertebral fracture was detected, the baseline
radiograph was evaluated as well. If the vertebral fracture was
already present at baseline, it was considered a baseline
prevalent fracture. If it was not present at baseline, the fracture
was defined to be incident.
Assessment of incident non-vertebral fracture
Follow-up started either at 1 January 1991 or, when later, at the
time of inclusion into the study. For this analysis follow-up
ended either at December 1999 or, when earlier, at the
participant’s death. The general practitioners of the participants
provided data on morbidity including non-vertebral fractures
and mortality. For approximately 80% of the study population,
medical events were reported through computerized general
practitioner diagnosis registers. For the remaining 20%,
research physicians collected data from the general practi-
tioners’ medical records of the study participants. All collected
fractures were verified by reviewing discharge reports
and letters from medical specialists. Fracture events were
coded independently by two research physicians according to
the International Classification of Diseases, 10th revision
(ICD-10). In case of discrepancy, consensus was attained in a
separate session. A medical expert in the field reviewed all
coded events for final classification.
Genotyping
Genomic DNA was isolated from peripheral leucocytes by
standard procedures. The molecular haplotyping of the
PvuII and XbaI RFLPs was performed as shown in Figure 1.
A 346 bp PCR fragment was generated by a forward primer
(ER-F: 50-GATATCCAGGGTTATGTGGCA-30) and a reverse
primer (ER-R: 50-AGGTGTTGCCTATTATATTAACCTTGA-30)
in a reaction mixture of 10 ml containing 10 ng of genomic
DNA, 50 mM KCl, 10 mM Tris–HCl ( pH 8.3), 1.5 mM MgCl2,
0.2 mM deoxy-NTP, 2 pM of each primer, and 0.2 U Super Taq
polymerase (HT Biotechnology Ltd, Cambridge, UK). The
reactions were performed in 384-well format in a thermocycler
(MJ-tetrad) with a cycling protocol of 94, 60 and 72C for 45 s
each for 30 cycles. Ten microliters of PCR product were
digested by addition of 5 ml of digestion mixture containing 5 U
PvuII, 7 U XbaI restriction enzyme (MBI Fermentas) and 1.5 ml
of ReactBuffer 2 (Life Technologies Inc.) and incubating for
90 min at 37C. The digestion products were analyzed by
electrophoresis in a 3% agarose gel in 0.5TBE (1
TBE¼ 89 mM Tris, 89 mM boric acid, 2 mM Na2EDTA) for
80 min at 125 V. Separation patterns were documented with a
digital camera (DC120, Kodak Company, Rochester, NY, USA)
under UV illumination (302 nm). Genotypes were defined as
haplotype numbers 1, 2, etc. by decreasing frequency in the
population. The correspondence between haplotype numbers,
RFLP alleles and nucleotides at positions 397int1 and
351int1 is shown in Figure 1.
A 160–194 bp PCR fragment was generated containing
the (TA)n VNTR using a FAM-labeled forward primer
(50-GACGCATGATATACTTCACC-30) and reverse primer
(50-GCAGAATCAAATATCCAGATG-30) in a reaction mixture
of 10 ml containing 10 ng of genomic DNA, 50 mM KCl, 10 mM
Tris–HCl ( pH 8.3), 1.5 mM MgCl2, 0.2 mM deoxy-NTP, 5 pM
of each primer, and 0.2 U Super Taq polymerase (HT
Biotechnology Ltd, Cambridge, UK). The reactions were
performed in 384-well format in a thermocycler (MJ-Tetrad)
with a cycling protocol of 94, 59 and 72C for 30 s each for
28 cycles. The labeled PCR products were analyzed on an ABI
3100 automated capillary DNA sequencer using Genescan
software (Applied Biosystems, Perkin Elmer, Capelle a/d
IJssel, The Netherlands). The length of alleles was determined
using internal size standards and genotypes were expressed as
size-allele combinations.
Statistical analysis
Estimation of PvuII–XbaI haplotype frequency. In our own
study, the PvuII–XbaI haplotypes were derived from direct
molecular haplotyping, as described above. Assessment of
the PvuII–XbaI haplotypes in other study populations,
described in previous manuscripts (12–15,17) was possible
when the combined genotype per individual was known. We
used these data to infer the frequency of the haplotypes present
in the population using the program 3LOCUS.pas (44).
Linkage disequilibrium analysis. The linkage disequilibrium
coefficient (D0) between each pair of alleles at both poly-
morphic loci was calculated. The coefficient is positive when
the alleles co-occur and is negative when alleles exclude each
other. D0 is calculated from the disequilibrium measure
D¼ h7 pq, where h is the frequency of the haplotype present
in the population and p and q are frequencies of the alleles
under investigation where p< q. In order to compare the degree
of disequilibrium between pairs of alleles with different
allele frequencies, the allele frequency-independent D0 was
calculated, where D0 ¼D/Dmax. If D< 0 then Dmax¼ pq,
and if D> 0 then Dmax¼ p(17 q). We used the program
PHASE (24) for determining the frequencies of the
TA–PvuII–XbaI haplotypes in different subpopulations.
Association analysis. Subjects were grouped according to
genotype. We grouped subjects by allele copy number (0, 1, 2)
for the PvuII–XbaI RFLP haplotypes 1 ( px), 2 (PX) and 3 (Px).
For the (TA)n VNTR, subjects were first grouped according to
carrier status of each allele separately. In a second analysis, the
(TA)n VNTR alleles were grouped according to the number of
TA-repeats: group ‘H’ includes alleles with a high number of
TA repeats [(TA)n 18] and group ‘L’ includes alleles with a
low number of TA repeats [(TA)n< 18]. The cut-off point
was based on the bimodal allele frequency distribution
(Fig. 2). Subjects were genotyped as ‘LL’, ‘LH’ or ‘HH’.
We allowed for three possible genetic models to explain
differences between groups, i.e. an allele dose effect, a
dominant effect or a recessive effect. Allele dose was defined
as the number of copies of a certain allele in the genotype. In
case of a consistent trend reflected as an allele-dose effect we
performed a linear regression analysis to quantify the
association. In case of a dominant or a recessive effect of
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the test allele, analysis of (co)variance [AN(C)OVA] was
performed to test for differences between two genotype groups.
For dominant alleles we compared test-allele carriers versus non-
carriers, while for recessive effects homozygous subjects for
the test allele were compared to heterozygous carriers com-
bined with non-carriers.
HWE was calculated according to standard procedures using
the chi-square analysis. To estimate non-vertebral fracture risk
we used Cox proportional hazard models, thereby taking
potential differences in follow-up time into account. P-values
were two-sided and 0.05 or less was considered significant. To
estimate the risk of vertebral fractures, odds ratios with 95%
confidence intervals (95% CI) were calculated using logistic
regression models. We were not able to use Cox proportional
hazard models since the exact time of event was not known. We
performed all vertebral fracture analysis seperately for both
prevalent and incident fractures, and always found the same
trends. Therefore, for reasons of power, all vertebral fracture
analysis presented were done with combined prevalent and
incident vertebral fractures. To calculate risk estimates and
95% CI for incremental classes of haplotypes (allele–dose
effects), the genetic variable was used as a continuous measure
in the model. All statistical analysis was performed using SPSS
version 10.1.0 (SPSS Inc., Chicago, IL, USA).
ACKNOWLEDGEMENTS
The authors thank Drs Albagha and Ralston (University of
Abderdeen, UK) for sharing unpublished sequence informa-
tion. The authors are very grateful to the DXA technicians,
L. Buist and H.W.M. Mathot. Moreover, we thank the
participants of the Rotterdam study and the many field workers
in the research center in Ommoord, The Netherlands. This
study was supported by the Netherlands Organization of
Scientific Research (grants 950-10-618, 903-46-178, 925-01-
010, 014-90-001).
REFERENCES
1. Anonymous (1993) Consensus Development Conference. Diagnosis,
prophylaxis, and treatment of osteoporosis. Am. J. Med., 94, 646–650.
2. Evans, R.A., Marel, G.M., Lancaster, E.K., Kos, S., Evans, M. and
Wong, S.Y. (1988) Bone mass is low in relatives of osteoporotic patients.
Ann. Intern. Med., 109, 870–873.
3. Pocock, N.A., Eisman, J.A., Hopper, J.L., Yeates, M.G., Sambrook, P.N.
and Eberl, S. (1987) Genetic determinants of bone mass in adults. A twin
study. J. Clin. Invest., 80, 706–710.
4. Khosla, S., Melton, L.J., III, Atkinson, E.J., O’Fallon, W.M., Klee, G.G. and
Riggs, B.L. (1998) Relationship of serum sex steroid levels and bone
turnover markers with bone mineral density in men and women: a key role
for bioavailable estrogen. J. Clin. Endocrinol. Metab., 83, 2266–2274.
5. Cummings, S.R., Browner, W.S., Bauer, D., Stone, K., Ensrud, K., Jamal, S.
and Ettinger, B. (1998) Endogenous hormones and the risk of hip and
vertebral fractures among older women. Study of Osteoporotic Fractures
Research Group. New Engl. J. Med., 339, 733–738.
6. Ettinger, B., Pressman, A., Sklarin, P., Bauer, D.C., Cauley, J.A. and
Cummings, S.R. (1998) Associations between low levels of serum
estradiol, bone density, and fractures among elderly women, the study of
osteoporotic fractures. J. Clin. Endocrinol. Metab., 83, 2239–2243.
7. Cauley, J.A., Seeley, D.G., Ensrud, K., Ettinger, B., Black, D. and
Cummings, S.R. (1995) Estrogen replacement therapy and fractures in
older women. Study of Osteoporotic Fractures Research Group. Ann.
Intern. Med., 122, 9–16.
8. Torgerson, D.J. and Bell-Syer, S.E. (2001) Hormone replacement therapy
and prevention of nonvertebral fractures: a meta-analysis of randomized
trials. JAMA, 285, 2891–2897.
9. Rossouw, J.E., Anderson, G.L., Prentice, R.L., La Croix, A.Z.,
Kooperberg, C., Stefanick, M.L., Jackson, R.D., Beresford, S.A.,
Howard, B.V., Johnson, K.C. et al. (2002) Risks and benefits of estrogen plus
progestin in healthy postmenopausal women, principal results from the
Women’s Health Initiative randomized controlled trial. JAMA, 288, 321–333.
10. Smith, E.P., Boyd, J., Frank, G.R., Takahashi, H., Cohen, R.M., Specker, B.,
Williams, T.C., Lubahn, D.B. and Korach, K.S. (1994) Estrogen resistance
caused by a mutation in the estrogen-receptor gene in a man. New Engl. J.
Med., 331, 1056–1061.
11. Korach, K.S. (1994) Insights from the study of animals lacking functional
estrogen receptor. Science, 266, 1524–1527.
12. Langdahl, B.L., Lokke, E., Carstens, M., Stenkjaer, L.L. and Eriksen, E.F.
(2000) A TA repeat polymorphism in the estrogen receptor gene is
associated with osteoporotic fractures but polymorphisms in the first
exon and intron are not. J. Bone Miner. Res., 15, 2222–2230.
13. Albagha, O.M., McGuigan, F.E., Reid, D.M. and Ralston, S.H. (2001)
Estrogen receptor alpha gene polymorphisms and bone mineral density:
haplotype analysis in women from the United Kingdom. J. Bone Miner.
Res., 16, 128–134.
14. Becherini, L., Gennari, L., Masi, L., Mansani, R., Massart, F., Morelli, A.,
Falchetti, A., Gonnelli, S., Fiorelli, G., Tanini, A. et al. (2000) Evidence of
a linkage disequilibrium between polymorphisms in the human estrogen
receptor alpha gene and their relationship to bone mass variation in
postmenopausal Italian women. Hum. Mol. Genet., 9, 2043–2050.
15. Kobayashi, S., Inoue, S., Hosoi, T., Ouchi, Y., Shiraki, M. and Orimo, H.
(1996) Association of bone mineral density with polymorphism of the
estrogen receptor gene. J. Bone Miner. Res., 11, 306–311.
16. Bagger, Y.Z., Jorgensen, H.L., Heegaard, A.M., Bayer, L., Hansen, L. and
Hassager, C. (2000) No major effect of estrogen receptor gene
polymorphisms on bone mineral density or bone loss in postmenopausal
Danish women. Bone, 26, 111–116.
17. Mizunuma, H., Hosoi, T., Okano, H., Soda, M., Tokizawa, T., Kagami, I.,
Miyamoto, S., Ibuki, Y., Inoue, S., Shiraki, M. et al. (1997) Estrogen
receptor gene polymorphism and bone mineral density at the lumbar spine
of pre- and postmenopausal women. Bone, 21, 379–383.
18. Han, K., Choi, J., Moon, I., Yoon, H., Han, I., Min, H., Kim, Y. and Choi, Y.
(1999) Non-association of estrogen receptor genotypes with bone mineral
density and bone turnover in Korean pre-, peri-, and postmenopausal
women. Osteoporosis Int., 9, 290–295.
19. Deng, H.W., Li, J., Li, J.L., Johnson, M., Gong, G., Davis, K.M. and Recker, R.R.
(1998) Change of bone mass in postmenopausal Caucasian women with and
without hormone replacement therapy is associated with vitamin D receptor and
estrogen receptor genotypes. Hum. Genet., 103, 576–585.
20. Willing, M., Sowers, M., Aron, D., Clark, M.K., Burns, T., Bunten, C.,
Crutchfield, M., D’Agostino, D. and Jannausch, M. (1998) Bone mineral
density and its change in white women: estrogen and vitamin D receptor
genotypes and their interaction. J. Bone Miner. Res., 13, 695–705.
21. Aerssens, J., Dequeker, J., Peeters, J., Breemans, S. and Boonen, S. (1998)
Lack of association between osteoarthritis of the hip and gene
polymorphisms of VDR, COL1A1, and COL2A1 in postmenopausal
women. Arthritis Rheum., 41, 1946–1950.
22. Yaich, L., Dupont, W.D., Cavener, D.R. and Parl, F.F. (1992) Analysis of the
PvuII restriction fragment-length polymorphism and exon structure of the
estrogen receptor gene in breast cancer and peripheral blood. Cancer Res.,
52, 77–83.
23. Stephens, M., Smith, N.J. and Donnelly, P. (2001) A new statistical method
for haplotype reconstruction from population data. Am. J. Hum. Genet., 68,
978–989.
24. Weel, A.E., Uitterlinden, A.G., Westendorp, I.C., Burger, H., Schuit, S.C.,
Hofman, A., Helmerhorst, T.J., van Leeuwen, J.P.T.M. and Pols, H.A.P.
(1999) Estrogen receptor polymorphism predicts the onset of natural and
surgical menopause. J. Clin. Endocrinol. Metab., 84, 3146–3150.
25. Ho, A.Y., Yeung, S.S. and Kung, A.W. (2000) PvuII polymorphisms of the
estrogen receptor alpha and bone mineral density in healthy southern
Chinese women. Calcif. Tissue Int., 66, 405–408.
26. Vandevyver, C., Vanhoof, J., Declerck, K., Stinissen, P., Vandervorst, C.,
Michiels, L., Cassiman, J.J., Boonen, S., Raus, J. and Geusens, P. (1999)
Lack of association between estrogen receptor genotypes and bone mineral
density, fracture history, or muscle strength in elderly women. J. Bone
Miner. Res., 14, 1576–1582.
Human Molecular Genetics, 2003, Vol. 12, No. 14 1753
27. Uitterlinden, A.G., Burger, H., Huang, Q., Fang, Y., McGuigan, F.E.,
Grant, S.F., Hofman, A., van Leeuwen, J.P.T.M., Pols, H.A.P. and
Ralston, S.H. (1998) Relation of alleles of the collagen type Ialpha1 gene
to bone density and the risk of osteoporotic fractures in postmenopausal
women. New Engl. J. Med., 338, 1016–1021.
28. Uitterlinden, A.G., Weel, A.E., Burger, H., Fang, Y., van Duijn, C.M.,
Hofman, A., van Leeuwen, J.P.T.M. and Pols, H.A.P. (2001)
Interaction between the vitamin D receptor gene and collagen
type Ialpha1 gene in susceptibility for fracture. J. Bone Miner. Res.,
16, 379–385.
29. Schuit, S.E., Bergink, A., van Meurs, J.B.J., van der Klift, M., Fang, Y.,
Arp, P., van Leeuwen, J.P.T.M., Pols, H.A.P. and Uitterlinden, A.G. (2002)
Height in elderly women is influenced by vitamin D receptor and Estrogen
Receptor polymorphisms. Osteoporosis Int., 13 (Suppl. 9), S62.
30. Lu, H., Higashikata, T., Inazu, A., Nohara, A., Yu, W., Shimizu, M.
and Mabuchi, H. (2002) Association of estrogen receptor-alpha
gene polymorphisms with coronary artery disease in patients
with familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol.,
22, 817–823.
31. Weiderpass, E., Persson, I., Melhus, H., Wedren, S., Kindmark, A. and
Baron, J.A. (2000) Estrogen receptor alpha gene polymorphisms and
endometrial cancer risk. Carcinogenesis, 21, 623–627.
32. Grant, S.F., Reid, D.M., Blake, G., Herd, R., Fogelman, I. and Ralston, S.H.
(1996) Reduced bone density and osteoporosis associated with a
polymorphic Sp1 binding site in the collagen type I alpha 1 gene. Nat.
Genet., 14, 203–205.
33. Herrington, D.M., Howard, T.D., Brosnihan, K.B., McDonnell, D.P., Li, X.,
Hawkins, G.A., Reboussin, D.M., Xu, J., Zheng, S.L., Meyers, D.A. et al.
(2002) Common estrogen receptor polymorphism augments effects of
hormone replacement therapy on E-selectin but not C-reactive protein.
Circulation, 105, 1879–1882.
34. Bennett, S.T., Wilson, A.J., Esposito, L., Bouzekri, N., Undlien, D.E.,
Cucca, F., Nistico, L., Buzzetti, R., Bosi, E., Pociot, F. et al. (1997)
Insulin VNTR allele-specific effect in type 1 diabetes depends on
identity of untransmitted paternal allele. The IMDIAB Group. Nat. Genet.,
17, 350–352.
35. Iwashita, S., Koyama, K. and Nakamura, Y. (2001) VNTR sequence on
human chromosome 11p15 that affects transcriptional activity. J. Hum.
Genet., 46, 717–721.
36. Chevalier, D., Cauffiez, C., Bernard, C., Lo-Guidice, J.M., Allorge, D.,
Fazio, F., Ferrari, N., Libersa, C., Lhermitte, M., D’Halluin, J.C. et al.
(2001) Characterization of new mutations in the coding sequence and
50-untranslated region of the human prostacylcin synthase gene (CYP8A1).
Hum. Genet., 108, 148–155.
37. Moore, M., Bracker, M., Sartoris, D., Saltman, P. and Strause, L. (1990)
Long-term estrogen replacement therapy in postmenopausal women
sustains vertebral bone mineral density. J. Bone Miner. Res., 5, 659–664.
38. Grey, A.B., Cundy, T.F. and Reid, I.R. (1994) Continuous combined
oestrogen/progestin therapy is well tolerated and increases bone density at
the hip and spine in post-menopausal osteoporosis. Clin. Endocrinol., 40,
671–677.
39. Duan, Y., Tabensky, A., DeLuca, V. and Seeman, E. (1997) The benefit of
hormone replacement therapy on bone mass is greater at the vertebral body
than posterior processes or proximal femur. Bone, 21, 447–451.
40. Hofman, A., Grobbee, D.E., de Jong, P.T.V.M. and van den Ouweland, F.A.
(1991) Determinants of disease in the elderly: the Rotterdam Elderly Study.
Eur. J. Epidemiol., 7, 403–422.
41. Burger, H., van Daele, P.L., Algra, D., van den Ouweland, F.A.,
Grobbee, D.E., Hofman, A., van Kuijk, C., Schutte, H.E., Birkenhager, J.C.
and Pols, H.A.P. (1994) The association between age and bone mineral
density in men and women aged 55 years and over: the Rotterdam Study.
Bone Miner., 25, 1–13.
42. McCloskey, E.V., Spector, T.D., Eyres, K.S., Fern, E.D., O’Rourke, N.,
Vasikaran, S. and Kanis, J.A. (1993) The assessment of vertebral deformity,
a method for use in population studies and clinical trials. Osteoporosis Int.,
3, 138–147.
43. Van der Klift, M., De Laet, C.E., McCloskey, E.V., Hofman, A. and Pols,
H.A.P. (2002) The incidence of vertebral fractures in men and women: the
Rotterdam Study. J. Bone Miner. Res., 17, 1051–1056.
44. Long, J.C., Williams, R.C. and Urbanek, M. (1995) An E-M algorithm
and testing strategy for multiple-locus haplotypes. Am. J. Hum. Genet.,
56, 799–810.
1754 Human Molecular Genetics, 2003, Vol. 12, No. 14
